An Exploratory Study of Gecacitinib in the Peri-Transplant Period for Patients With Myeloid Neoplasms and Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
This is a single-arm, single-center exploratory study evaluating the safety and efficacy of gecacitinib administered in the peri-transplant period in patients with myeloid neoplasms and myelofibrosis (MF) who are scheduled to undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT).Approximately 10 eligible patients will receive oral gecacitinib starting 13 weeks before transplantation. Treatment will continue through the peri-transplant period and for up to 24 weeks after hematopoietic reconstitution. The primary endpoint is the engraftment rate at day +28 post-transplant. Secondary endpoints include poor graft function rate, grade III-IV acute GVHD rate, overall survival, infection rate, and bone marrow fibrosis grade changes.
• Patients must voluntarily sign the informed consent form, be aged ≥18 years at the time of informed consent, and may be of either sex.
• Diagnosed with myeloid neoplasms according to 2022 WHO diagnostic criteria
• Bone marrow fibrosis grade ≥2 according to 2016 WHO myelofibrosis grading criteria
• Undergoing first allogeneic hematopoietic stem cell transplantation
• ECOG performance status: 0-2
• Able to swallow tablets
• Able to comply with study procedures and follow-up requirements